Roy M. Gulick, M.D.

Infectious Disease
Infectious Disease
Roy Gulick

Dr. Gulick is Professor of Medicine and Chief of the Division of Infectious Diseases at Weill Medical College of Cornell University, and Attending Physician at the New York Presbyterian Hospital in New York City.

Dr. Gulick currently conducts clinical research, sees patients with infectious diseases, and teaches medicine. He is board certified in internal medicine and infectious diseases.

Dr. Gulick's research interests include designing, conducting and analyzing clinical trials to refine antiretroviral therapy strategies for HIV treatment and prevention and assess antiretroviral agents with new mechanisms of action. He currently serves as Principal Investigator of the Cornell HIV Clinical Trials Unit of the AIDS Clinical Trials Group (ACTG), sponsored by the National Institutes of Health.

Dr. Gulick received his undergraduate degree from Johns Hopkins University in 1982. In his early career, he worked as a Biologist in the Medicinal Chemistry Laboratory at the National Institutes of Health in Bethesda, MD. He went on to earn his MD degree at Columbia University College of Physicians and Surgeons in 1986 and his Master of Public Health degree at Harvard University in 1993, focusing on clinical trial design. After completing his internship and residency in internal medicine at Columbia-Presbyterian Medical Center in 1989, Dr. Gulick held fellowships in infectious diseases at Beth Israel Hospital and Massachusetts General Hospital in Boston from 1989-1991.

Dr. Gulick joined the faculty of the Harvard Medical School in 1991, serving as the Medical Director of the Virology Research Clinic and Instructor of Medicine in the Division of Infectious Diseases at Beth Israel Hospital in Boston. In 1994, he returned to New York City to join the faculty of New York University School of Medicine where he was Director of the HIV Research Clinic at Bellevue Hospital and an attending physician in the Division of Infectious Diseases.

Dr. Gulick joined the faculty of Weill Cornell Medical College as an Assistant Professor of Medicine in 1998. He became Director of the HIV Clinical Trials Unit in 1999, serving through 2008. He was promoted to Associate Professor of Medicine in 2001 and Professor of Medicine in 2007. In 2009, he became the Chief of the Division of Infectious Diseases.

He serves as a Board Member of the International Antiviral Society-USA, and as a member of the Panel on Clinical Practices for Treatment of HIV Infection of the U.S. Department of Health and Human Services. He previously served as the Chairman of the Antiviral Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) and as Co-Chairman of the Forum for Collaborative HIV Research. He is a member of the American Society of Clinical Investigation (ASCI), the Infectious Diseases Society of America (IDSA), the Infectious Diseases Society of New York (IDSNY), and the International AIDS Society (IAS) and has presented at national and international meetings and published widely.

Insurances

Insurance Plans Accepted

The following represents most of the managed care plans accepted by this physician. If your insurance carrier does not appear here please feel free to contact this physician or this physician's practice as they may have individual contracts not included on this site.

  • AETNA [PPO]
  • AETNA [HMO]
  • AETNA [Medicare]
  • Aetna - Weill Cornell [POS]
  • Affinity Health Plan
  • CIGNA
  • Empire Blue Cross/Blue Shield [Mediblue (Senior)]
  • Empire Blue Cross/Blue Shield [HMO]
  • Empire Blue Cross/Blue Shield [EPO]
  • Empire Blue Cross/Blue Shield [PPO]
  • Fidelis Care
  • GHI [CBP]
  • Health First
  • Health Insurance Plan of NY (HIP) [Medicare]
  • Health Insurance Plan of NY (HIP) [Medicaid]
  • Health Insurance Plan of NY (HIP)
  • Health Plus - Amerigroup
  • Medicare [Medicare]
  • Oxford Health Plans [Liberty]
  • Oxford Health Plans [Medicare Advantage]
  • Oxford Health Plans [Freedom]
  • Rockefeller University - CoreSource
  • United Health Care [Medicare]
  • United Health Care
  • United Health Care [Community Plan]

Publications

(Selected from more than 130 total.)

1. Gulick RM, Mellors JW, Havlir D, Eron JJ, Gonzalez C, McMahon D, Richman DD, Valentine FT, Jonas L, Meibohm A, Emini EA, Chodakewitz JA. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 1997;337:734-739.

2. Gulick RM, Mellors JW, Havlir D, Eron JJ, Gonzales C, McMahon D, Jonas L, Meibohm A, Holder D, Schleif WA, Condra JH, Emini EA, Isaacs R, Chodakewitz JA, Richman DD. Simultaneous vs. sequential initiation of therapy with indinavir, zidovudine, and lamivudine for HIV-1 infection: 100 week follow-up. JAMA 1998;280:35-41.

3. Gulick RM, McAuliffe V, Holden-Wiltse J, Crumpacker C, Liebes L, Stein DS, Meehan P, Hussey S, Forcht J, Valentine FT. Phase I studies of hypericin, the active compound in St. John's Wort, as an antiretroviral agent in HIV infected adults: AIDS Clinical Trials Group Protocols 150 + 258. Ann Intern Med 1999;130:510-514.

4. Gulick RM, Mellors JW, Havlir D, Eron JJ, Meibohm A, Condra JH, Valentine FT, McMahon D, Gonzalez C, Jonas L, Emini E, Chodakewitz J, Isaacs R, Richman DD. Suppression of HIV viremia for 3 years with indinavir, zidovudine, and lamivudine. Ann Intern Med 2000;133:35-39.

5. Gulick RM, Hu XJ, Fiscus SA, Fletcher CV, Haubrich R, Cheng H, Acosta E, Lagakos S, Snyder S, Fischl M, Pettinelli C, Katzenstein D. Saquinavir in combination with ritonavir or nelfinavir together with delavirdine, adefovir dipivoxil, or both in HIV-infected subjects with virologic failure on indinavir -- ACTG 359. J Infect Dis 2000;182:1375-1384.

6. Gulick RM, Smeaton LM, D'Aquila RT, Eron JJ, Currier JS, Gerber JG, Sommadossi J-P, Tung R, Snyder S, Kuritzkes DR, Murphy RL. Indinavir, nevirapine, stavudine and lamivudine for HIV-infected, amprenavir-experienced subjects: ACTG Protocol 373. J Infect Dis 2001;183:715-721.

7. Gulick RM, Hu J, Fiscus SA, Fletcher CV, Haubrich R, Cheng H, Acosta E, Lagakos SW, Swanstrom R, Freimuth W, Snyder S, Mills C, Fischl M, Pettinelli C, Katzenstein D. Durability of response to treatment for antiretroviral-experienced subjects: 48 week results from AIDS Clinical Trials Group Study 359. J Infect Dis 2002;186:626-633.

8. Casau NC, Glesby MJ, Paul S, Gulick RM. Efficacy and treatment-limiting toxicity with the concurrent use of lopinavir/ritonavir and a third protease inhibitor in treatment-experienced HIV-infected patients. J Acquir Imm Def Syndr 2003;32:494-498.

9. Gulick RM, Meibohm A, Havlir D, Eron JJ, Mosley A, Chodakewitz JA, Isaacs R, Gonzalez C, McMahon D, Richman DD, Robertson M, Mellors JW. Six-year follow-up of HIV-1-infected adults in a clinical trial of antiretroviral therapy with indinavir, zidovudine, and lamivudine. AIDS 2003;17:2345-9.

10. Gulick RM, Ribaudo HJ, Shikuma CM, Lustgarten S, Squires KE, Meyer WA, Acosta EP, Schackman BR, Pilcher CD, Murphy RL, Maher WE, Witt MD, Reichman RC, Snyder S, Klingman KL, Kuritzkes DR. Triple nucleoside analogue vs. efavirenz-containing regimens for the initial treatment of HIV-1 infection: AIDS Clinical Trials Group (ACTG) Study A5095. N Engl J Med 2004;350:1850-61.

11. Fletcher CV, Jiang H, Brundage RC, Acosta EP, Haubrich R, Katzenstein D, Gulick RM. Sex differences in saquinavir pharmacology and virologic response in AIDS Clinical Trials Group (ACTG) Study 359. J Infect Dis 2004;189:1176-1184.

12. Swanstrom R, Bosch RJ, Katzenstein D, Cheng H, Jiang H, Hellman N, Haubrich R, Fiscus SA, Fletcher CV, Acosta EP, Gulick RM. Weighted phenotypic susceptibility scores (PSS) are predictive of HIV-1 RNA response in protease inhibitor-experienced HIV-1-infected subjects. J Infect Dis 2004;190:886-893.

13. Fletcher CV, Testa MA, Brundage RC, Chesney MA, Haubrich R, Acosta EP, Martinez A, Jiang H, Gulick RM. Four measures of antiretroviral medication adherence and virologic response in AIDS Clinical Trials Group (ACTG) study 359. J Acquir Immune Defic Syndr 2005;40;301-306.

14. Severe P, Leger P, Charles M, Noel F, Bonhomme G, Bois G, George E, Kenel-Pierre S, Wright P, Gulick R, Johnson WD, Pape JW, Fitzgerald DW. Antiretroviral therapy in a 1000 patients with AIDS in Haiti. N Engl J Med 2005;353:2325-2334.

15. Gulick RM, Ribaudo HJ, Shikuma CM, Lalama C, Schackman BR, Meyer III WA, Acosta EP, Schouten J, Squires KE, Pilcher CD, Murphy RL, Koletar SL, Carlson M, Reichman RC, Bastow B, Klingman KL, Kuritzkes DR. Three- vs. four-drug antiretroviral regimen for the initial treatment of HIV-1 infection: a randomized controlled trial. JAMA 2006:296:769-781.

16. Wilkin TJ, Su Z, Kuritzkes DR, Hughes M, Flexner C, Gross R, Coakley E, Greaves W, Godfrey C, Skolnik PR, Timpone J, Rodriguez B, Gulick RM. HIV Type 1 chemokine coreceptor use among antiretroviral-experienced patients screened for a clinical trial of a CCR5 inhibitor: AIDS Clinical Trial Group 5211. Clin Infect Dis 2007;44:591-595.

17. Kuritzkes DR, Ribaudo HJ, Squires KE, Koletar SL, Santana J, Riddler SA, Reichman R, Shikuma C, Meyer WA, Klingman K, Gulick RM. Plasma HIV-1 RNA dynamics in antiretroviral-naive subjects receiving either triple-nucleoside or efavirenz-containing regimens: ACTG A5166s. J Infect Dis 2007;195:1169-1176.

18. Gulick RM, Lalama CM, Ribaudo HJ, Shikuma CM, Schackman BR, Schouten J, Squires KE, Koletar SL, Pilcher CD, Reichman RC, Klingman KL, Kuritzkes DR. Intensification of a triple-nucleoside regimen with tenofovir or efavirenz in HIV-1-infected patients with virologic suppression. AIDS 2007;21:813-823.

19. Gulick RM, Su Z, Flexner C, Hughes MD, Skolnik PR, Wilkin TJ, Gross R, Krambrink A, Coakley E, Greaves WL, Zolopa A, Reichman R, Godfrey C, Hirsch M, Kuritzkes DR. Phase II study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-infected, treatment-experienced patients: ACTG 5211. J Infect Dis 2007;196:304-312.

20. Schackman BR, Ribaudo HJ, Krambrink A, Hughes V, Kuritzkes DR, Gulick RM. Racial differences in virologic failure associated with adherence and quality of life on efavirenz-containing regimens for initial HIV therapy: Results of ACTG A5095. J Acquir Immune Defic Syndr 2007;46:547-554.

21. Kuritzkes DR, Lalama CM, Ribaudo HJ, Marcial M, Meyer WA, Shikuma C, Johnson VA, Fiscus S, D'Aquila RT, Schackman BR, Acosta EP, Gulick RM. Pre-existing non-nucleoside reverse transcriptase inhibitor resistance predicts virologic failure of an efavirenz-based regimen in treatment-naïve HIV-1-infected subjects. J Infect Dis 2008;197:867-870.

22. Ribaudo HJ, Kuritzkes DR, Lalama CM, Schouten JT, Schackman BR, Acosta EP, Gulick RM. Activity of efavirenz-based regimens in treatment-naïve patients across a range of pre-treatment HIV-1 RNA level and CD4 cell counts: ACTG A5095. J Infect Dis 2008;197:1006-1010.

23. Tsibris AMN, Sagar M, Gulick RM, Su Z, Hughes M, Greaves W, Subramanian M, Flexner C, Giguel F, Leopold KE, Coakley E, Kuritzkes DR. In vivo emergence of vicriviroc resistance in a human immunodeficiency virus type 1 subtype C-infected subject. J Virol 2008;82:8210-8214.

24. Gulick RM, Lalezari J, Goodrich J, Clumeck N, DeJesus E, Horban A, Nadler J, Clotet B, Karlsson A, Wohlfeiler M, Montana JB, McHale M, Sullivan J, Ridgway C, Felstead S, Dunne MW, van der Ryst E, Mayer H. Maraviroc for previously treated patients with R5 HIV-1 infection. N Engl J Med 2008;359:1429-1441.

25. Su Z, Gulick RM, Krambrink A, Coakley E, Hughes MD, Han D, Flexner C, Wilkin TJ, Skolnik PR, Greaves WL, Kuritzkes DR, Reeves JD. Response to vicriviroc in treatment-experienced subjects, as determined by an enhanced-sensitiviey corecetpor tropism assay: reanalysis of AIDS Clinical Trials Group A5211. J Infect Dis 2009;200:1724-1728.

26. Schouten JT, Krambrink A, Ribaudo HJ, Kmack A, Webb N, Shikuma C, Kuritzkes DR, Gulick RM. Substitution of nevirapine because of efavirenz toxicity in AIDS Clinical Trials Group A5095. Clin Infect Dis 2010;50:787-791.

27. Severe P, Juste MA, Ambroise A, Eliacin L, Marchand C, Apollon S, Edwards A, Bang H, Nicotera J, Godfrey C, Gulick RM, Johnson WD, Pape JW, Fitzgerald DW. Early versus standard antiretroviral therapy for HIV-infected adults in Haiti. N Engl J Med 2010;363:257-265.

28. Wilkin TJ, Su Z, Krambrink A, Long J, Greaves W, Gross R, Hughes MD, Flexner C, Skolnik PR, Coakley E, Godfrey C, Hirsch M, Kuritzkes DR, Gulick RM. Three-Year safety and efficacy of vicriviroc, a CCR5 antagonist, in HIV-1-infected, treatment-experienced patients. JAIDS 2010;54:470-476.

29. Wilkin TJ, Ribaudo H, Tenorio AR, Gulick RM. The relationship of CCR5 antagonists to CD4+ T-cell gain: A meta-regression of recent clinical trials in treatment-experienced HIV-infected patients. HIV Clin Trials 2010;11:351-358.

30. Wilkin TJ, Goetz MB, Leduc R, Skowron G, Su Z, Chan ES, Heera J, Chapman D, Spritzler J, Reeves JD, Gulick RM, Coakley E. Reanalysis of coreceptor tropism in HIV-1-infected adults using a phenotypic assay with enhanced sensitivity. Clin Infect Dis 2011;52:925-928.

Honors and Awards

Alpha Omega Alpha, National Medical Honor Society, Columbia College of Physicians and Surgeons, 1986

Most Scientifically Innovative Presentation, Second International Workshop on Salvage Therapy for HIV Infection; Toronto, Canada, 1999

Companero (Friend) Award, Latino Commission on AIDS, New York, NY, for commitment to HIV/AIDS research, 2002.

Mid-Career Investigator Award in Patient-Oriented Research (K24), National Institute of Allergy and Infectious Disease, National Institutes of Health, 2003-2013.

Excellence in Teaching Award (Advanced Basic Science Course), Weill Cornell Medical College, 2005

Advisory Committee Service Award in Recognition of Distinguished Service, U.S. Food and Drug Administration, 2005

Clinical Infectious Diseases Award for Outstanding Review, 2006

Elected to American Society for Clinical Investigation (ASCI), 2006

Research in Action Award, Treatment Action Group, 2009

Elected to Fellowship, Infectious Diseases Society of America, 2009

Lifetime Achievement Award for invaluable contributions in the field of HIV medicine, medical education, and research, HIV Congress, Mumbai, India, 2012